Phosphodiesterase-5 Inhibitors in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension: Diagnosis and Evidence-Based Treatment

Volumn , Issue , 2008, Pages 105-125

  Ghofrani, Hossein A ^a   Seeger, Werner ^a   Grimminger, Friedrich ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

PAH PDE5 inhibitors; Phosphodiesterase (PDE5) gene expression; Phosphodiesterase 5 inhibitor development; Prostanoid and sildenafil combinational therapy; SUPER 1 (Sildenafil Use in Pulmonary HypERtension) study

Indexed keywords

EID: 79952982887     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470997390.ch6     Document Type: Chapter

References (140)

1. Abrams, D., Schulze-Neick, I. and Magee, A.G. (2000) Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 84, E4.
2. Agusti, A.G. and Rodriguez-Roisin, R. (1993) Effect of pulmonary hypertension on gas exchange. Eur. Respir. J. 6, 1371-1377.
3. Ahn, H.S. et al. (1991) Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv. Exp. Med. Biol. 308, 191-197.
4. Alaeddini, J. et al. (2004) Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am. J. Cardiol. 94, 1475-1477.
5. Alp, S., Skrygan, M., Schmidt, W.E. and Bastian, A. (2005) Sildenafil improves hemodynamic parameters in COPD-an investigation of six patients. Pulm. Pharmacol. Ther. 19, 386-390.
6. Anversa, P., Capasso, J.M., Olivetti, G. and Sonnenblick, E.H. (1992) Cellular basis of ventricular remodeling in hypertensive cardiomyopathy. Am. J. Hypertens. 5, 758-770.
7. Anversa, P. et al. (1995) Ischemic cardiomyopathy: myocyte cell loss, myocyte cellular hypertrophy and myocyte cellular hyperplasia. Ann. N.Y. Acad. Sci. 752, 47-64.
8. Arruda-Olson, A.M. et al. (2002) Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 287, 719-725.
9. Atz, A.M. and Wessel, D.L. (1999) Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 91, 307-310.
10. Barbera, J.A., Peinado, V.I. and Santos, S. (2003) Pulmonary hypertension in chronic obstructive pulmonary disease. Eur. Respir. J. 21, 892-905.
11. Beavo, J.A. (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75, 725-748.
12. Belch, J.J. and Ho, M. (1996) Pharmacotherapy of Raynaud's phenomenon. Drugs 52, 682-695.
13. Bloch, W. et al. (1998) Evidence for the involvement of endothelial nitric oxide synthase from smooth muscle cells in the erectile function of the human corpus cavernosum. Urol. Res. 26, 129-135.
14. Bocchi, E.A. et al. (2002) Sildenafil effects on exercise, neurohormonal activation and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 106, 1097-1103.
15. Bohle, R.M. et al. (2000) Cell type-specific mRNA quantitation in non-neoplastic tissues after laser-assisted cell picking. Pathobiology 68, 191-195.
16. Boin, F. and Wigley, F.M. (2005) Understanding, assessing and treating Raynaud's phenomenon. Curr. Opin. Rheumatol. 17, 752-760.
17. Boshier, A., Wilton, L.V. and Shakir, S.A. (2004) Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. BJU. Int. 93, 796-801.
18. Braner, D.A., Fineman, J.R., Chang, R. and Soifer, S.J. (1993) M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am. J. Physiol. 264, H252-H258.
19. Carlsen, J., Kjeldsen, K. and Gerstoft, J. (2002) Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 16, 1568-1569.
20. Celoria, G.C., Friedell, G.H. and Sommers, S.C. (1960) Raynaud's disease and primary pulmonary hypertension. Circulation 22, 1055-1059.
21. Cohen, A.H. et al. (1996) Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J. Clin. Invest. 97, 172-179.
22. Corbin, J.D. and Francis, S.H. (1999) Cyclic GMP phosphodiesterase-5: target of sildenafil. J. Biol. Chem. 274, 13729-13732.
23. Corbin, J.D. and Francis, S.H. (2002) Pharmacology of phosphodiesterase-5 inhibitors. Int. J. Clin. Pract. 56, 453-459.
24. Corbin, J.D., Beasley, A., Blount, M.A. and Francis, S.H. (2005) High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem. Biophys. Res. Commun. 334, 930-938.
25. Cunningham, A.V. and Smith, K.H. (2001) Anterior ischemic optic neuropathy associated with viagra. J. Neuroophthalmol. 21, 22-25.
26. D'Alonzo, G.E. et al. (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115, 343-349.
27. DeBusk, R.F. et al. (2004) Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am. J. Cardiol. 93, 147-153.
28. Desouza, C. et al. (2002) Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 25, 1336-1339.
29. Dousa, T.P. (1999) Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int. 55, 29-62.
30. Egan, R. and Pomeranz, H. (2000) Sildenafil (Viagra) associated anterior ischemic optic neuropathy. Arch. Ophthalmol. 118, 291-292.
31. Fawcett, L. et al. (2000) Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc. Natl. Acad. Sci. USA 97, 3702-3707.
32. Fink, T.L. et al. (1999) Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). J. Biol. Chem. 274, 34613-34620.
33. Fisher, P.W. et al. (2005) Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111, 1601-1610.
34. Fox, K.M. et al. (2003) Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur. Heart J. 24, 2206-2212.
35. Francis, S.H., Turko, I.V. and Corbin, J.D. (2001) Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65, 1-52.
36. Francis, S.H. et al. (1998) Ligand-induced conformational changes in cyclic nucleotide phosphodiesterases and cyclic nucleotide-dependent protein kinases. Methods 14, 81-92.
37. Fraunfelder, F.W., Pomeranz, H.D. and Egan, R.A. (2006) Nonarteritic anterior ischemic optic neuropathy and sildenafil. Arch. Ophthalmol. 124, 733-734.
38. Freitas, D. et al. (2006) Sildenafil improves quality of life in men with heart failure and erectile dysfunction. Int. J. Impot. Res. 18, 210-212.
39. Fries, R., Shariat, K., von Wilmowsky, H. and Bohm, M. (2005) Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 112, 2980-2985.
40. Galie, N. et al. (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353, 2148-2157.
41. Gbekor, E. et al. (2002) Phosphodiesterase 5 inhibitor profiles against all human phosphodiesterase families: Implications for use as pharmacological tools. J. Urol. 167, 246.
42. German, Z. et al. (2000) Molecular basis of cell-specific endothelial nitric-oxide synthase expression in airway epithelium. J. Biol. Chem. 275, 8183-8189.
43. Ghofrani, H.A., Osterloh, I.H. and Grimminger, F. (2006) Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Disc. 5, 689-702.
44. Ghofrani, H.A. et al. (2002a) Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. 136, 515-522.
45. Ghofrani, H.A. et al. (2002b) Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360, 895-900.
46. Ghofrani, H.A. et al. (2003a) Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 167, 1139-1141.
47. Ghofrani, H.A. et al. (2003b) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol. 42, 158-164.
48. Ghofrani, H.A. et al. (2004a) Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43, 68S-72S.
49. Ghofrani, H.A. et al. (2004b) Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol. 44, 1488-1496.
50. Ghofrani, H.A. et al. (2004c) Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann. Intern. Med. 141, 169-177.
51. Giordano, D et al. (2001) Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim. Biophys. Acta 1539, 16-27.
52. Glavas, N.A. et al. (2001) T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc. Natl. Acad. Sci. USA 98, 6319-6324.
53. Gopal, V.K., Francis, S.H. and Corbin, J.D. (2001) Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur. J. Biochem. 268, 3304-3312.
54. Gore, J. and Silver, R. (2005) Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann. Rheum. Dis. 64, 1387.
55. Gorkin, L., Hvidsten, K., Sobel, R.E. and Siegel, R. (2006) Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int. J. Clin. Pract. 60, 500-503.
56. Grimminger, F. et al. (1995) Nitric oxide generation and hypoxic vasoconstriction in bufferperfused rabbit lungs. J. Appl. Physiol. 78, 1509-1515.
57. Guazzi, M. et al. (2004) The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency and oxygen uptake kinetics in chronic heart failure. J. Am. Coll. Cardiol. 44, 2339-2348.
58. Halcox, J.P. et al. (2002) The effect of sildenafil on human vascular function, platelet activation and myocardial ischemia. J. Am. Coll. Cardiol. 40, 1232-1240.
59. Hanson, K.A. et al. (1998) Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am. J. Physiol. 275, L931-L941.
60. Hassan, M.A. and Ketat, A.F. (2005) Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC. Pharmacol. 5, 10.
61. Hattenhauer, M.G. et al. (1997) Incidence of nonarteritic anterior ischemic optic neuropathy. Am. J. Ophthalmol. 123, 103-107.
62. Hayashi, M. et al. (1998) Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3',5'-cyclic nucleotide phosphodiesterase. Biochem. Biophys. Res. Commun. 250, 751-756.
63. Haynes, J., Jr., Kithas, P.A., Taylor, A.E. and Strada, S.J. (1991) Selective inhibition of cGMPinhibitable cAMP phosphodiesterase decreases pulmonary vasoreactivity. Am. J. Physiol. 261, H487-H492.
64. Herrmann, H.C., Chang, G., Klugherz, B.D. and Mahoney, P.D. (2000) Hemodynamic effects of sildenafil in men with severe coronary artery disease. N. Engl. J. Med. 342, 1622-1626.
65. Higenbottam, T. (2005) Pulmonary hypertension and chronic obstructive pulmonary disease: a case for treatment. Proc. Am. Thorac. Soc. 2, 12-19.
66. Hirata, K., Adji, A., Vlachopoulos, C. and O'Rourke, M.F. (2005) Effect of Sildenafil on Cardiac Performance in Patients With Heart Failure. Am. J. Cardiol. 96, 1436-1440.
67. Hoeper, M.M. et al. (2004) Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 24, 1007-1010.
68. Hsu, A.R. et al. (2006) Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. J. Appl. Physiol. 100, 2031-2040.
69. Huai, Q. et al. (2004) Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity. J. Biol. Chem. 279, 13095-13101.
70. Ichinose, F., Adrie, C., Hurford, W.E. and Zapol, W.M. (1995) Prolonged pulmonary vasodilator action of inhaled nitric oxide by Zaprinast in awake lambs. J. Appl. Physiol 78, 1288-1295.
71. Ichinose, F. et al. (1998) Selective pulmonary vasodilation induced by aerosolized zaprinast. Anesthesiology 88, 410-416.
72. Ide, H. et al. (1999) Regulation of pulmonary circulation by alveolar oxygen tension via airway nitric oxide. J. Appl. Physiol 87, 1629-1636.
73. Itoh, T. et al. (2004) A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 169, 34-38.
74. Jessup, M. and Brozena, S. (1995) Heart failure. N. Engl. J. Med. 348, 2007-2018.
75. Johnson, L.N. and Arnold, A.C. (1994) Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. J. Neuroophthalmol. 14, 38-44.
76. Kallenberg, C.G. (1995) Overlapping syndromes, undifferentiated connective tissue disease and other fibrosing conditions. Curr. Opin. Rheumatol. 7, 568-573.
77. Kamata,Y., Kamimura, T., Iwamoto, M. and Minota, S. (2005) Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis. Clin. Exp. Dermatol. 30, 451.
78. Kasimir, M.T. et al. (2004) Reverse cardiac remodelling in patients with primary pulmonary hypertension after isolated lung transplantation. Eur. J. Cardiothorac. Surg. 26, 776-781.
79. Katz, S.D. et al. (2000) Acute type 5 phosphodiesterase inhibition with sildenafil enhances flowmediated vasodilation in patients with chronic heart failure. J. Am. Coll. Cardiol. 36, 845-851.
80. Katz, S.D. et al. (2005) Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am. J. Cardiol. 95, 36-42.
81. Kentera, D. and Susic, D. (1980) Dynamics of regression of right ventricular hypertrophy in rats with hypoxic pulmonary hypertension. Respiration 39, 272-275.
82. Kothari, S.S. and Duggal, B. (2002) Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J. 54, 404-409.
83. Lepore, J.J. et al. (2005) Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 127, 1647-1653.
84. Lichtenstein, J.R. (2003) Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al. Arthritis Rheum. 48, 282-283.
85. Lucas, K.A. et al. (2000) Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 52, 375-414.
86. Mahmud, A., Hennessy, M. and Feely, J. (2001) Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. J. Hum. Hypertens. 15, 707-713.
87. Maurice, D.H. et al. (2003) Cyclic nucleotide phosphodiesterase activity, expression and targeting in cells of the cardiovascular system. Mol. Pharmacol. 64, 533-546.
88. Michelakis, E.D. (2003) The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Fail. Rev. 8, 5-21.
89. Michelakis, E.D. et al. (2003) Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108, 2066-2069.
90. Mickley, H. and Poulsen, T.S. (2004) Use of sildenafil is safe in men with congestive heart failure. Arch. Intern. Med. 164, 2068.
91. Mikhail, N. (2004) Efficacy and safety of sildenafil in patients with congestive heart failure. Arch. Intern. Med. 164, 2067-2068.
92. Moncada, S., Palmer, R.M. and Higgs, E.A. (1991) Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43, 109-142.
93. Moncada, I. et al. (2004) Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur. Urol. 46, 357-360.
94. Mullershausen, F. et al. (2003) Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J. Cell Biol. 160, 719-727.
95. Naeije, R. (2005) Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2, 20-22.
96. Nagamine, J., Hill, L.L. and Pearl, R.G. (2000) Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension. Crit. Care Med. 28, 2420-2424.
97. Nangle, M.R., Cotter, M.A. and Cameron, N.E. (2003) An in vitro study of corpus cavernosum and aorta from mice lacking the inducible nitric oxide synthase gene. Nitric Oxide 9, 194-200.
98. O'Blenes, S.B. et al. (2001) Hemodynamic unloading leads to regression of pulmonary vascular disease in rats. J. Thorac. Cardiovasc. Surg. 121, 279-289.
99. Ockaili, R., Salloum, F., Hawkins, J. and Kukreja, R.C. (2002) Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am. J. Physiol. Heart Circ. Physiol 283, H1263-H1269.
100. Oliver, J. and Webb, D.J. (2002) Sildenafil for "blue babies". Such unlicensed drug use might be justified as last resort. Brit. Med. J. 325, 1174.
101. Parker, J.D. and Parker, J.O. (1998) Nitrate therapy for stable angina pectoris. N. Engl. J. Med. 338, 520-531.
102. Patole, S. and Travadi, J. (2002) Sildenafil for "blue babies". Ethics, conscience and science have to be balanced against limited resources. Brit. Med. J. 325, 1174.
103. Pelouch,V. et al. (1997) Regression of chronic hypoxia-induced pulmonary hypertension, right ventricular hypertrophy and fibrosis: effect of enalapril. Cardiovasc. Drugs Ther. 11, 177-185.
104. Pfeifer, A. et al. (1999) Structure and function of cGMP-dependent protein kinases. Rev. Physiol. Biochem. Pharmacol. 135, 105-149.
105. Pomeranz, H.D. and Bhavsar, A.R. (2005) Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases. J. Neuroophthalmol. 25, 9-13.
106. Pomeranz, H.D., Smith, K.H., Hart, W.M., Jr. and Egan, R.A. (2002) Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology 109, 584-587.
107. Pope, J. et al. (2000) Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane. Database. Syst. Rev.CD000953.
108. Prasad, S.,Wilkinson, J. and Gatzoulis, M.A. (2000) Sildenafil in primary pulmonary hypertension. N. Engl. J. Med. 343, 1342.
109. Pyne, N.J. and Furman, B.L. (2003) Cyclic nucleotide phosphodiesterases in pancreatic islets. Diabetologia 46, 1179-1189.
110. Reichenberger, F. et al. (2007) Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 30, 922-927.
111. Rich, S. and Brundage, B.H. (1987) High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 76, 135-141.
112. Richalet, J.P. et al. (2005) Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am. J. Respir. Crit. Care Med. 171, 275-281.
113. Rosenkranz, S. et al. (2003) Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon. Ann. Intern. Med. 139, 871-873.
114. Rossaint, R. et al. (1993) Inhaled nitric oxide for the adult respiratory distress syndrome. N. Engl. J. Med. 328, 399-405.
115. Sanchez, L.S. et al. (1998) Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pediatr. Res. 43, 163-168.
116. Sastry, B.K., Narasimhan, C., Reddy, N.K. and Raju, B.S. (2004) Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J. Am. Coll. Cardiol. 43, 1149-1153.
117. Sastry, B.K. et al. (2002) A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J. 54, 410-414.
118. Schermuly, R.T. et al. (2004) Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 169, 39-45.
119. Schulz, R. et al. (2000) Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax 55, 1046-1051.
120. Schumacher, Y.O., Zdebik, A., Huonker, M. and Kreisel, W. (2001) Sildenafil in HIV-related pulmonary hypertension. AIDS 15, 1747-1748.
121. Sebkhi, A. et al. (2003) Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 107, 3230-3235.
122. Simonneau, G. et al. (2008) Safety and Efficacy of Sildenafil-Epoprostenol Combination Therapy in Patients with Pulmonary Arterial Hypertension (PAH). Annals of Internal Medicine 2008 (in press).
123. Sitbon, O. et al. (1998) Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension [see comments]. Eur. Respir. J. 12, 265-270.
124. Smith,W.M. and Kroop, I.G. (1957) Raynaud's disease in primary pulmonary hypertension. J. Am. Med. Assoc. 165, 1245-1248.
125. Soderling, S.H., Bayuga, S.J. and Beavo, J.A. (1998) Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc. Natl. Acad. Sci. USA 95, 8991-8996.
126. Spriestersbach, R. et al. (1995) On-line measurement of nitric oxide generation in buffer-perfused rabbit lungs. J. Appl. Physiol. 78, 1502-1508.
127. Takimoto, E. et al. (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. 11, 214-222.
128. Thusu, K.G., Morin, F.C., III, Russell, J.A. and Steinhorn, R.H. (1995) The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. Am. J. Respir. Crit. Care Med. 152, 1605-1610.
129. Voelkel, N.F. and Cool, C.D. (2003) Pulmonary vascular involvement in chronic obstructive pulmonary disease. Eur. Respir. J. Suppl 46, 28s-32s.
130. Webster, L.J., Michelakis, E.D., Davis, T. and Archer, S.L. (2004) Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. Arch. Intern. Med. 164, 514-520.
131. Weissmann, N. et al. (2000) Nitric oxide (NO)-dependent but not NO-independent guanylate cyclase activation attenuates hypoxic vasoconstriction in rabbit lungs. Am. J. Respir. Cell Mol. Biol. 23, 222-227.
132. Wharton, J. et al. (2005) Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am. J. Respir. Crit. Care Med. 172, 105-113.
133. Wilkens, H. et al. (2001) Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104, 1218-1222.
134. Wilkins, M.R. et al. (2005) Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study. Am. J. Respir. Crit. Care Med. 171, 1292-1297.
135. Wysowski, D.K., Farinas, E. and Swartz, L. (2002) Comparison of reported and expected deaths in sildenafil (Viagra) users. Am. J. Cardiol. 89, 1331-1334.
136. Yang, Q. et al. (1994) A novel cyclic GMP stimulated phosphodiesterase from rat brain. Biochem. Biophys. Res. Commun. 205, 1850-1858.
137. Zhang, R. et al. (2002) Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 33, 2675-2680.
138. Zhao, L. et al. (2001) Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104, 424-428.
139. Zhao, L. et al. (2003) M.R. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity. Circulation 107, 234-237.
140. Ziegler, J.W. et al. (1998) Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Am. J. Respir. Crit Care Med. 158, 1388-1395.